Tarsus Pharmaceuticals TARS

$ 46.64 0.12%

Quarterly report 2024-Q3
added 11-13-2024

Tarsus Pharmaceuticals Financial Statements 2011-2024 | TARS

Annual Financial Statements Tarsus Pharmaceuticals

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Market Cap	1.17 B	978 M	452 M	707 M	-	-	-	-	-	-	-	-	-
Shares	29.4 M	24.6 M	20.6 M	18.8 M	-	-	-	-	-	-	-	-	-
Historical Prices	39.7	39.7	22.5	41.3	-	-	-	-	-	-	-	-	-
Net Income	-136 M	-62.1 M	-13.8 M	-	-4.67 M	-1.32 M	-	-	-	-	-	-	-
Revenue	17.4 M	25.8 M	57 M	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-143 M	-62.7 M	-12.2 M	-27 M	-4.3 M	-	-	-	-	-	-	-	-
Interest Expense	3.35 M	2.2 M	-73 K	-	-	-	-	-	-	-	-	-	-
EBITDA	-142 M	-62.4 M	-11.9 M	-26.9 M	-4.22 M	-1.35 M	-	-	-	-	-	-	-
Operating Expenses	161 M	88.5 M	69.2 M	27 M	4.3 M	1.35 M	-	-	-	-	-	-	-
General and Administrative Expenses	109 M	44.9 M	25.4 M	8.17 M	1.14 M	449 K	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Income Statement Tarsus Pharmaceuticals

	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Shares	38.4 M	37.8 M	35.3 M	34.2 M	30.6 M	26.8 M	26.7 M	26.7 M	26.7 M	24.3 M	20.7 M	20.7 M	20.6 M	20.6 M	20.3 M	20.3 M	2.73 M	2.65 M	2.65 M	2.65 M	2.47 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-23.4 M	-33.3 M	-35.7 M	-	-39.1 M	-31.4 M	-23.4 M	-	-22.5 M	-5.74 M	-20.2 M	-	-15.7 M	6.34 M	10.4 M	-	-10.1 M	-3.25 M	-1.96 M	-	-681 K	-831 K	-1.74 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenue	48.1 M	40.8 M	27.6 M	-	1.87 M	-	2.5 M	-	-	15.3 M	539 K	-	1.24 M	22 M	33.4 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	522 K	33 K	-	65 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-25.2 M	-33.3 M	-37.7 M	-	-40.9 M	-32.8 M	-25 M	-	-22.9 M	-5.22 M	-19.5 M	-	-15.7 M	7.28 M	10.7 M	-	-10.1 M	-3.26 M	-2.12 M	-	-633 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expense	67 K	-59 K	983 K	-	-48 K	-47 K	684 K	-	633 K	544 K	316 K	-	5 K	-39 K	-34 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-25 M	-33.2 M	-37.5 M	-	-40.7 M	-32.6 M	-24.8 M	-	-22.8 M	-5.12 M	-19.4 M	-	-15.6 M	7.41 M	10.8 M	-	-10.1 M	-3.25 M	-2.1 M	-	-624 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	20.5 M	20.1 M	-	16.9 M	14.7 M	22.7 M	-	10.1 M	3.26 M	2.12 M	-	633 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General and Administrative Expenses	57.9 M	58.8 M	51.6 M	-	30.3 M	20.3 M	15.1 M	-	12 M	10.4 M	7.95 M	-	6.67 M	6.79 M	5.16 M	-	2.15 M	1.53 M	606 K	-	234 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency